Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 73% Improvement Relative Risk Improvement in dyspnea 38% Improvement in Ct score 22% c19early.org/o Pourdowlat et al. Colchicine for COVID-19 RCT LATE Is late treatment with colchicine beneficial for COVID-19? RCT 202 patients in Iran Lower hospitalization (p=0.0037) and improved recovery (p=0.025) Pourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319 Favors colchicine Favors control
Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial
Pourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319
Pourdowlat et al., Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized.., Phytotherapy Research, doi:10.1002/ptr.7319
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.
risk of hospitalization, 72.8% lower, RR 0.27, p = 0.004, treatment 5 of 102 (4.9%), control 18 of 100 (18.0%), NNT 7.6.
relative improvement in dyspnea, 37.5% better, RR 0.62, p = 0.03, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.
relative improvement in Ct score, 22.4% better, RR 0.78, p = 0.048, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pourdowlat et al., 2 Feb 2022, Randomized Controlled Trial, Iran, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Received: 10 May 2021 Revised: 29 September 2021 Accepted: 12 October 2021 DOI: 10.1002/ptr.7319 RESEARCH ARTICLE Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial Guitti Pourdowlat1 | Fatemeh Saghafi2 | Abolfazl Mozafari3 | Adeleh Sahebnasagh4 | Atefeh Abedini1 | Mohsen Nabi Meybodi5 | Ali Salehi Nezamabadi6 | Seyed Ruhollah Mousavinasab7 | Arda Kiani8 9 10 | | Mehdi Gholmzadeh Baeis | Esmaeil Eidani12 | Hanieh Raji | Nadia Soltani Abdolrahim Sadeghi Yakhdani13 | Fatemeh Movaseghi3 | Solomon Habtemariam14 | Zohreh Akhoundi Meybodi15 | 11 Mohsen Gholinataj Jelodar16 1 Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran 2 Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 3 Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran 4 Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran 5 Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran 6 Department of Cardiology, Tehranpars Hospital, Tehran, Iran 7 Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 8 Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran 9 Department of Internal Medicine, Air pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 10 Pharmaceutical Sciences Research Center, School of Pharmacy, Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 11 Department of Radiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran 12 NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran 13 Department of Radiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 14 Pharmacognosy Research Laboratories and Herbal Analysis Services UK, University of Greenwich, Kent, UK 15 Infectious Disease Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran 16 Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Correspondence Mohsen Gholinataj Jelodar, Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email: dr.natajm@gmail.com Abstract Colchicine has shown clinical benefits in the management of COVID-19 via its antiinflammatory effect. However, the exact role of colchicine in COVID-19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID-19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3-day course of 0.5 mg colchicine followed by a 12-day course of 1 mg colchicine in combination with standard care or a 15-day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or List of Abbreviations:..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit